Simon Scholes

Ben Jackson

Jeff Jones

Sushila Hernandez

Alistair Campbell

Jeffrey Jones

Joseph Pantginis

- Pharming Group N.V. announced the implementation of an organizational restructuring, which includes a **20% net reduction in non-commercial and non-medical headcount**, primarily at its Netherlands headquarters.  **[1828316_0001828316-25-000045_pharminggroupprovidesupdat.htm:0]** 
- The company remains on track to reduce total general and administrative (G&A) expenses by **15% or US$10 million annually**.  **[1828316_0001828316-25-000045_pharminggroupprovidesupdat.htm:0]** 
- Pharming anticipates recording approximately **$7 million in one-time restructuring costs** in the **fourth quarter of 2025** related to the headcount reduction.  **[1828316_0001828316-25-000045_pharminggroupprovidesupdat.htm:0]**

Pharming Group N.V. Implements Organizational Restructuring and Provides G&A Expense Reduction Update

- Pharming Group N.V. announced the U.S. FDA's acceptance of its supplemental New Drug Application (sNDA) for **leniolisib** to treat children aged **4 to 11 years** with Activated Phosphoinositide 3-Kinase Delta Syndrome (APDS).  **[1828316_0001828316-25-000043_pharminggroupannouncesusfd.htm:0]** 
- The FDA granted **Priority Review** for the sNDA, with a Prescription Drug User Fee Act (PDUFA) target action date of **January 31, 2026**.  **[1828316_0001828316-25-000043_pharminggroupannouncesusfd.htm:0]** 
- If approved, leniolisib would be the **first and only treatment** indicated for children aged 4 to 11 years with APDS, building on its existing U.S. FDA approval for patients **12 years of age and older**.  **[1828316_0001828316-25-000043_pharminggroupannouncesusfd.htm:0]** **[1828316_0001828316-25-000043_pharminggroupannouncesusfd.htm:1]**

Pharming Group (PHAR)